Skip to main content
ANAB
NASDAQ Life Sciences

EcoR1's Nodelman Lifts AnaptysBio Stake to 27.8% After $17.2M Buying Run

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$47.74
Mkt Cap
$1.399B
52W Low
$22.063
52W High
$72.36
52W Position info
116% above low
Off High info
34% below high
Rel. Volume info
1.1× avg
Market data snapshot near publication time

ANAB has more than doubled off its 52-week low of $22.063.

Summary

EcoR1 Capital and Oleg Nodelman disclosed a 27.8% AnaptysBio stake, 8,254,674 shares bought for $154.7 million cumulatively, after adding 374,580 shares for $17.2 million on November 16-18. The 13D/A also states Nodelman may push for board and management action, including a sale or change in control.


Key Events · Ownership and Investor Activity · ANAB

  • EcoR1 Stake Reaches 27.8%

    EcoR1 Capital, Oleg Nodelman and EcoR1 Capital Fund Qualified, L.P. report beneficial ownership of 8,254,674 shares, 27.8% of the 29,729,847 shares outstanding as of November 9, 2026; the Qualified Fund alone holds 7,642,937 shares, or 25.7%.

  • $17.2M Added Over Three Days

    The buying broke down as 84,120 shares at $45.6624 on 11/16, 152,367 at $45.6553 on 11/17 and 138,093 at $46.5419 on 11/18, totaling 374,580 shares for $17,224,592.78.

  • Cumulative Cost Basis $154.7M

    For the 8,254,674 shares, the funds paid an aggregate $154,747,392.28, about $18.75 per share on average, against today's $47.74 price.

  • Board Seat With Action Rights

    Item 4 states Nodelman is a director and the reporting persons may recommend action to management, the board and stockholders, potentially including mergers, asset sales, changes in control or capitalization changes; they report no present plan to do so.


Analysis · ANAB · Life Sciences

The headline number is the stake: EcoR1 Capital and Oleg Nodelman now hold 8,254,674 AnaptysBio shares, 27.8% of the 29,729,847 shares outstanding as of November 9, 2026, after buying 374,580 shares for $17.2 million on November 16-18. Those trades were already on the Form 4 filed earlier today, so what is new here is the size of the position and its cost: $154.7 million cumulatively, an average of roughly $18.75 a share, well below today's $47.74. That is a large, deeply profitable holder who also sits on the board. For governance, the Item 4 language is the part that matters: Nodelman may recommend actions to management, the board and stockholders, including mergers, asset sales, changes in control or capitalization changes. With a Delaware Chancery ruling on the dostarlimab contract dispute still pending per the Q3 10-Q, a 27.8% holder with board access has real leverage over whatever comes next.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANAB was trading at $47.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $22.06 to $72.36. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANAB - Latest Insights

ANAB
Nov 18, 2026, 6:56 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $47.06
Real-time Price: $47.74 info
Change: +$0.680 (+1%) info
Market Cap: $1.399B info
ANAB
Nov 12, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.74 info
Change: -$0.030 (-0.06%) info
Market Cap: $1.399B info
ANAB
Nov 12, 2026, 4:16 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $47.77
Real-time Price: $47.74 info
Change: -$0.030 (-0.06%) info
Market Cap: $1.399B info
ANAB
Oct 20, 2026, 3:49 PM EDT
Source: Seeking Alpha
Importance Score:
7
Price at Filing: $45.00
Real-time Price: $47.74 info
Change: +$2.74 (+6%) info
Market Cap: $1.399B info
ANAB
Oct 19, 2026, 2:18 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $49.23
Real-time Price: $47.74 info
Change: -$1.49 (-3%) info
Market Cap: $1.399B info